An Open-Label Phase 1 Clinical Trial of the Allogeneic Side Population Adipose-Derived Mesenchymal Stem Cells in Sma Type 1 Patients Publisher Pubmed



Mohseni R^{1, 2} ; Hamidieh AA^{1, 3} ; Shoaehassani A⁴ ; Ghahvechiakbari M⁵ ; Majma A⁶ ; Mohammadi M⁷ ; Nikougoftar M⁸ ; Shervinbadv R⁷ ; Ai J² ; Montazerlotfelahi H⁹ ; Ashrafi MR^{1, 7} Show Affiliations
Source: Neurological Sciences Published:2022

Abstract

Introduction: Spinal muscular atrophy (SMA), an autosomal recessive neurodegenerative disorder of alpha motor neurons of spinal cord associated with progressive muscle weakness and hypotonia, is the most common genetic cause of infant mortality. Although there is few promising treatment for SMA, but the field of translational research is active in it, and stem cell-based therapy clinical trials or case studies are ongoing. Combination of different therapeutic approaches for noncurative treatments may increase their effectiveness and compliance of patients. We present a phase 1 clinical trial in patients with SMA1 who received side population adipose-derived mesenchymal stem cells (SPADMSCs). Methods: The intervention group received three intrathecal administrations of escalating doses of SPADMSCs and followed until 24 months or the survival time. The safety analysis was assessed by controlling the side effects and efficacy evaluations performed by the Hammersmith Infant Neurological Examination (HINE), Ballard score, and electrodiagnostic (EDX) evaluation. These evaluations were performed before intervention and at the end of the follow-up. Results: The treatment was safe and well tolerated, without any adverse event related to the stem cell administration. One of the patients in the intervention group was alive after 24 months of study follow-up. He is a non-sitter 62-month-old boy with appropriate weight gain and need for noninvasive ventilation (NIV) for about 8 h per day. Clinical scores, need for supportive ventilation, and number of hospitalizations were not meaningful parameters in the response of patients in the intervention and control groups. All five patients in the intervention group showed significant improvement in the motor amplitude response of the tibial nerve (0.56mV; p: 0.029). Conclusion: This study showed that SPADMSCs therapy is tolerable and safe with promising efficacy in SMA I. Probably same as other treatment strategies, early intervention will increase its efficacy and prepare time for more injections. We suggest EDX evaluation for the follow-up of treatment efficacy. © 2021, Fondazione Societa Italiana di Neurologia.